CD33 and neoplasm: In the MV4-11 model, mice treated with the SAR T cell and anti-E3–anti-CD33 taFv combination experienced major responses to the therapy, with improved tumor control in all treated mice, and a complete response observed in two out of seven mice, which was not seen under any of the negative control conditions.